167 related articles for article (PubMed ID: 21562972)
21. Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. II. Side-effects.
Winther L; Malling HJ; Mosbech H
Allergy; 2000 Sep; 55(9):827-35. PubMed ID: 11003446
[TBL] [Abstract][Full Text] [Related]
22. Recent advances in immunotherapy for allergic diseases.
El-Qutob D; Mencia G; Fernandez-Caldas E
Recent Pat Inflamm Allergy Drug Discov; 2014 Jan; 8(1):24-35. PubMed ID: 24237114
[TBL] [Abstract][Full Text] [Related]
23. Possible relationship between systemic side effects and sensitization to rPar j 2 in allergic patients submitted to an ultra-rush (20 min) sublingual immunotherapy and selected by component resolved diagnosis.
Rossi RE; Monasterolo G; Coco G; Operti D
Int Arch Allergy Immunol; 2005 Oct; 138(2):105-10. PubMed ID: 16174987
[TBL] [Abstract][Full Text] [Related]
24. Long-term immunological effects of Japanese cedar pollen-based subcutaneous immunotherapy.
Inuo C; Ando H; Tanaka K; Nakajima Y; Tsuge I; Urisu A; Kondo Y
Allergol Int; 2018 Jul; 67(3):408-410. PubMed ID: 29198713
[No Abstract] [Full Text] [Related]
25. Dimerisation increases the immunogenicity of recombinant Parj1/Parj2 allergens.
Barletta B; Butteroni C; Bonura A; Bondi ML; Colombo P; Di Felice G
Int J Immunopathol Pharmacol; 2015 Mar; 28(1):142-5. PubMed ID: 25816419
[TBL] [Abstract][Full Text] [Related]
26. Pretreatment IgE sensitization patterns determine the molecular profile of the IgG4 response during updosing of subcutaneous immunotherapy with timothy grass pollen extract.
Schmid JM; Würtzen PA; Dahl R; Hoffmann HJ
J Allergy Clin Immunol; 2016 Feb; 137(2):562-70. PubMed ID: 26141262
[TBL] [Abstract][Full Text] [Related]
27. Sublingual immunotherapy with recombinant Mal d 1 downregulates the allergen-specific Th2 response.
Kitzmüller C; Jahn-Schmid B; Kinaciyan T; Bohle B
Allergy; 2019 Aug; 74(8):1579-1581. PubMed ID: 30887520
[No Abstract] [Full Text] [Related]
28. Vaccination of nonallergic individuals with recombinant hypoallergenic fragments of birch pollen allergen Bet v 1: Safety, effects, and mechanisms.
Campana R; Marth K; Zieglmayer P; Weber M; Lupinek C; Zhernov Y; Elisyutina O; Khaitov M; Rigler E; Westritschnig K; Berger U; Wolkersdorfer M; Horak F; Horak F; Valenta R
J Allergy Clin Immunol; 2019 Mar; 143(3):1258-1261. PubMed ID: 30471304
[No Abstract] [Full Text] [Related]
29. Efficacy and safety of 4 months of sublingual immunotherapy with recombinant Mal d 1 and Bet v 1 in patients with birch pollen-related apple allergy.
Kinaciyan T; Nagl B; Faustmann S; Frommlet F; Kopp S; Wolkersdorfer M; Wöhrl S; Bastl K; Huber H; Berger U; Bohle B
J Allergy Clin Immunol; 2018 Mar; 141(3):1002-1008. PubMed ID: 28870463
[TBL] [Abstract][Full Text] [Related]
30. Kinetics, cross-reactivity, and specificity of Bet v 1-specific IgG4 antibodies induced by immunotherapy with birch pollen.
Subbarayal B; Schiller D; Möbs C; de Jong NW; Ebner C; Reider N; Bartel D; Lidholm J; Pfützner W; Gerth van Wijk R; Vieths S; Bohle B
Allergy; 2013 Nov; 68(11):1377-86. PubMed ID: 24053565
[TBL] [Abstract][Full Text] [Related]
31. Fusion proteins consisting of Bet v 1 and Phl p 5 form IgE-reactive aggregates with reduced allergenic activity.
Najafi N; Hofer G; Gattinger P; Smiljkovic D; Blatt K; Selb R; Stoecklinger A; Keller W; Valent P; Niederberger V; Thalhamer J; Valenta R; Flicker S
Sci Rep; 2019 Mar; 9(1):4006. PubMed ID: 30850635
[TBL] [Abstract][Full Text] [Related]
32. Birch pollen immunotherapy leads to differential induction of regulatory T cells and delayed helper T cell immune deviation.
Möbs C; Slotosch C; Löffler H; Jakob T; Hertl M; Pfützner W
J Immunol; 2010 Feb; 184(4):2194-203. PubMed ID: 20048125
[TBL] [Abstract][Full Text] [Related]
33. Different IgE reactivity profiles in birch pollen-sensitive patients from six European populations revealed by recombinant allergens: an imprint of local sensitization.
Movérare R; Westritschnig K; Svensson M; Hayek B; Bende M; Pauli G; Sorva R; Haahtela T; Valenta R; Elfman L
Int Arch Allergy Immunol; 2002 Aug; 128(4):325-35. PubMed ID: 12218371
[TBL] [Abstract][Full Text] [Related]
34. Component-resolved diagnosis of baker's allergy based on specific IgE to recombinant wheat flour proteins.
Sander I; Rihs HP; Doekes G; Quirce S; Krop E; Rozynek P; van Kampen V; Merget R; Meurer U; Brüning T; Raulf M
J Allergy Clin Immunol; 2015 Jun; 135(6):1529-37. PubMed ID: 25576081
[TBL] [Abstract][Full Text] [Related]
35. Tolerance and immunological changes of chemically modified allergen vaccine of Parietaria judaica in accelerated schedules.
Asturias JA; Ferrer A; Arilla MC; Andreu C; Madariaga B; Martínez A
Clin Exp Immunol; 2007 Mar; 147(3):491-6. PubMed ID: 17302898
[TBL] [Abstract][Full Text] [Related]
36. The current state of recombinant allergens for immunotherapy.
Pauli G; Malling HJ
Curr Opin Allergy Clin Immunol; 2010 Dec; 10(6):575-81. PubMed ID: 20859201
[TBL] [Abstract][Full Text] [Related]
37. Specific immunotherapy.
Larché M
Br Med Bull; 2000; 56(4):1019-36. PubMed ID: 11359635
[TBL] [Abstract][Full Text] [Related]
38. How molecular diagnosis may modify immunotherapy prescription in multi-sensitized pollen-allergic children.
Del-Río Camacho G; Montes Arjona AM; Fernández-Cantalejo Padial J; Rodríguez Catalán J
Allergol Immunopathol (Madr); 2018; 46(6):552-556. PubMed ID: 30017214
[TBL] [Abstract][Full Text] [Related]
39. Reducing allergenicity by altering allergen fold: a mosaic protein of Phl p 1 for allergy vaccination.
Ball T; Linhart B; Sonneck K; Blatt K; Herrmann H; Valent P; Stoecklinger A; Lupinek C; Thalhamer J; Fedorov AA; Almo SC; Valenta R
Allergy; 2009 Apr; 64(4):569-80. PubMed ID: 19243361
[TBL] [Abstract][Full Text] [Related]
40. Immunological comparison of allergen immunotherapy tablet treatment and subcutaneous immunotherapy against grass allergy.
Aasbjerg K; Backer V; Lund G; Holm J; Nielsen NC; Holse M; Wagtmann VR; Würtzen PA
Clin Exp Allergy; 2014 Mar; 44(3):417-28. PubMed ID: 24734285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
